AMH
PCRX icon

Apollo Management Holdings’s Pacira BioSciences PCRX Stock Holding History

Apollo Management Holdings’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150,000
Closed -$8.74M – 261
2022
Q2 		$8.74M Buy
+150,000
New +$9.83M 0.06% 77

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Apollo Management Holdings's PCRX Position: Q2 2024 in Review

Apollo Management Holdings sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 2,114 shares — an estimated $61.8K sold.

Apollo Management Holdings first reported a position in PCRX in Q2 2022 and held it in 8 quarters. The position peaked at $634K in Q2 2022. 280 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

  • Apollo Management Holdings reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
  • Apollo Management Holdings sold 2,114 Pacira BioSciences shares in Q2 2024, an estimated $61.8K.
  • Apollo Management Holdings first reported a position in Pacira BioSciences in Q2 2022 and held it in 8 quarters.
  • Apollo Management Holdings's Pacira BioSciences position peaked at $634K in Q2 2022.
  • 280 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Apollo Management Holdings's 13F filing for Q2 2024, filed 14 Aug 2024.